Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:

NCT ID: NCT05712473 Not yet recruiting - Prostate Cancer Clinical Trials

An Observational Registry Assessing the Impact of PYLARIFY® (Piflufolastat F18) PET in Patients With Prostate Cancer

Start date: February 2023
Phase:
Study type: Observational [Patient Registry]

The goal of this observational research is to assess the real-world clinical utility of PYLARIFY PET through evaluation of long-term outcomes for prostate cancer patients who are eligible for a PSMA/PET scan. Participants will be enrolled at their physician's office at the time of referral for PYLARIFY PET and will be followed for up to 5 years. Data concerning their prostate cancer diagnostics and treatment will be collected at 6-month intervals.

NCT ID: NCT05690399 Not yet recruiting - Prostate Cancer Clinical Trials

Evaluation of Clinical and Pathological Characteristics and Routine Treatment of Patients With Prostate Cancer

Start date: January 2023
Phase:
Study type: Observational

To evaluate clinical and pathological characteristics and treatment protocol and outcomes of patients with prostate cancer in 2 centers of Asyut from 2013 to 2023

NCT ID: NCT05681416 Not yet recruiting - Prostate Cancer Clinical Trials

Prostate Cancer Prevention Clinic for Men With Risk of Familial Prostate Cancer

ProFam-Risk
Start date: February 1, 2023
Phase: N/A
Study type: Interventional
Read more »
NCT ID: NCT05644197 Not yet recruiting - Prostate Cancer Clinical Trials

Multidisciplinary Care After Prostatectomy

MCAP
Start date: January 2023
Phase: N/A
Study type: Interventional

This is a pilot, prostective, comparative, randomized, monocentric open-label study whose main objective is to determine whether appropriate psychological, nutritional and physical activity support can improve the quality of life of carrier patients. localized prostate cancer treated by prostatectomy

NCT ID: NCT05614700 Not yet recruiting - Prostate Cancer Clinical Trials

Prostate Reirradiation Toxicity Outcomes Feasibility Study

RO-PIP
Start date: November 15, 2022
Phase: N/A
Study type: Interventional

The RO-PIP trial aims to determine the feasibility of recruitment to a trial randomising patients to salvage ultra-hypofractionated external beam radiotherapy or high dose rate brachytherapy and provide prospective data on patient recorded toxicity outcomes that will inform a future phase III trial.

NCT ID: NCT05610852 Not yet recruiting - Prostate Cancer Clinical Trials

Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound

Start date: June 1, 2024
Phase: N/A
Study type: Interventional

This study aims to compare the novel single-port robotic partial prostatectomy to High-intensity focused ultrasound (HIFU) in patients with low to intermediate risk localized prostate cancer. These interventions have become acceptable focal therapies prevalent with beneficial oncologic outcomes and therefore need to be examined further.

NCT ID: NCT05590624 Not yet recruiting - Prostate Cancer Clinical Trials

Metabolic Impact of Prospective Controlled Mediterranean Type Diets on Prostate Cancer

Start date: August 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to examine the impact of Mediterranean-type diets on the metabolism of men with localized prostate cancer. The optimal diet for men with a suspected diagnosis of Prostate Cancer (PCa) is currently unknown. More specifically, the suggested benefits of low carbohydrate and low fat diets in PCa are not determined.

NCT ID: NCT05576766 Not yet recruiting - Prostate Cancer Clinical Trials

Enhanced Recovery After Surgery (ERAS) Pathway in Patients Undergoing Robot-Assisted Laparoscopic Radical Prostatectomy

Start date: October 2022
Phase: N/A
Study type: Interventional

Prostate cancer ranks second among all malignances in men and has become a significant threat to men's health. Robot-assisted laparoscopic radical prostatectomy (RARP) has become a standard treatment for prostate cancer. How to improve recovery following RARP surgery is worth investigating. The enhanced recovery after surgery (ERAS) pathway involves a series of evidence-based procedures. It is aimed to reduce the systemic stress response to surgery and shorten the length of hospital stay. This randomized trial aims to investigate the impact of Enhanced Recovery After Surgery (ERAS) Pathway on early outcomes after RARP surgery.

NCT ID: NCT05574647 Not yet recruiting - Prostate Cancer Clinical Trials

Imperial Prostate 7 - Prostate Assessment Using Comparative Interventions - Fast Mri and Image-fusion for Cancer

IP7-PACIFIC
Start date: October 1, 2022
Phase: N/A
Study type: Interventional

To evaluate the role of biparametric MRI and image-fusion targeted biopsies for the detection of prostate cancer. To determine whether biparametric MRI (bpMRI) could be recommended as an alternative to multiparametric MRI (mpMRI) for the detection of clinically significant prostate cancers in patients at risk. To determine whether image-fusion targeted biopsy is better than visual-registration (cognitive) targeted biopsy at detecting clinically significant prostate cancers in patients requiring prostate biopsy due to a suspicious MRI.

NCT ID: NCT05568537 Not yet recruiting - Prostate Cancer Clinical Trials

Prostate MRI and Pylarify PSMA PET/CT

Start date: June 15, 2024
Phase: Phase 4
Study type: Interventional

This is a voluntary research study to find out how using technology including advanced magnetic resonance imaging (MRI) and prostate-specific membrane antigen - positron emission tomography (PSMA-PET) scan imaging, in addition to combined prostate treatment using radiation therapy, brachytherapy (internal radiation treatment using small radioactive seeds placed inside the body) and androgen deprivation therapy (drug therapy to suppress hormones) can help doctors see, track and predict tumor response to treatment for prostate cancer patients. Participation in this study will consist of radiation planning and simulation, magnetic resonance imaging (MRI) and positron emission tomography and computed tomography scan (PET/CT). One MRI and PSMA PET/CT scan will be done prior to the start of first external beam radiation therapy (EBRT) fraction. At mid-treatment prior to the second brachytherapy fraction, an MRI and PSMA PET/CT will be done. A third scan will be performed after 75% testosterone recovery or 12 months post androgen deprivation therapy (ADT) [whichever comes first].